Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
NCT02566044
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Cystic Fibrosis
Interventions
OTHER:
Placebo
DRUG:
QBW276
Sponsor
Novartis Pharmaceuticals